Evidence map›Paper›PMID 15208667›Full record

ArticleOncogene2004

p53-dependent transcription can exhibit both on/off and graded response after genotoxic stress.

Arvi Jõers, Viljar Jaks, Johanna Kase, Toivo Maimets

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Surf the post-translational modification network of p53 regulation.International journal of biological sciences · 2012
    Review
  6. Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
  7. Article
  8. Article
  9. Article
  10. Binary gene induction and protein expression in individual cells.Theoretical biology & medical modelling · 2006
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Arvi JõersDepartment of Cell Biology, Institute of Molecular and Cell Biology, Tartu University, Riia 23, 51010, Tartu, Estonia. ajoers@ebc.es
Viljar Jaks
Johanna Kase
Toivo Maimets

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The p53 protein is a central player in cellular response to DNA damage. Induction of p53 by DNA-damaging agents involves elevation of its steady-state level and activation of its potency as a transcription factor. In the cell population, these responses can occur either homogeneously (where every single cell responds simultaneously and similarly to its neighbor) or heterogeneously (where only some cells of a population respond and the number of these increases with increasing dose of inducer). We have studied here the p53 response to DNA-damaging agents (camptothecin, mitomycin C) in individual cells. We show that the level of p53 protein is increased in every single cell of the population homogeneously, while the p53-dependent transcription can be subject to an on/off-type response. Depending on the structure of the target promoter, p53-dependent transcription can be regulated according to the binary or graded model. The on/off-type transcriptional activation pattern of p53 defines two distinct subpopulations of cells after DNA damage.

Indexed as

Base SequenceBlotting, WesternDNA DamageDNA PrimersFluorescent Antibody TechniqueGreen Fluorescent ProteinsLuminescent ProteinsMutagensTranscription, GeneticTumor Suppressor Protein p53DNA PrimersGreen Fluorescent ProteinsLuminescent ProteinsMutagensTumor Suppressor Protein p53

Identifiers

PMID15208667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.